Meningococcal Haemophilus influenzae type b Conjugate Vaccine Brand Name– MENHIBRIX
What is Meningococcal Haemophilus influenzae type b Conjugate Vaccine
Meningococcal Haemophilus influenzae type b Conjugate Vaccine (MenHibrix) is a vaccine for the prevention of disease caused by Neisseria meningitidis serogroups C and Y and Haemophilus influenzae type b.
The vaccine is approved as a four-dose series to be administered to infants ages 6 weeks through 18 months. It is the first meningococcal vaccine to be approved in infants as young as 6 weeks of age.
The rates of meningococcal disease are highest among children < 2 years of age with serogroups B, C, and Y being the major causes of disease in the United States.
Infections due to N. meningitidis or H. influenzae can lead to serious complications, such as mental retardation, hearing loss, or death.
The disease often progresses rapidly and, in the early stages, can be difficult to distinguish from other common childhood diseases.
MenHibrix was approved by the FDA in June 2012.
Indications
- Haemophilus influenzae type b prophylaxis
- meningococcal infection prophylaxis
For simultaneous meningococcal infection prophylaxis due to Neisseria meningitidis serogroups C and Y and Haemophilus influenzae type b prophylaxis
Side Effects
- anaphylactoid reactions
- angioedema
- apnea
- drowsiness
- edema
- erythema
- fever
- hypotonia
- injection site reaction
- irritability
- rash
- syncope
- urticaria
Monitoring Parameters
- laboratory monitoring not necessary
Contraindications
- anticoagulant therapy
- breast-feeding
- coagulopathy
- Guillain-Barre syndrome
- hemophilia
- immunosuppression
- pregnancy
- premature neonates
- syncope
- thrombocytopenia
- visual disturbance
- vitamin K deficiency
Interactions
- Ocrelizumab
- Siponimod
